Incidence, causes and outcome of new-onset heart failure in children with no known heart disease in a French area

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic by the WHO in March 2020. As of August 2021, more than 220 countries have been affected, accounting for 211,844,613 confirmed cases and 4,432,802 deaths worldwide. A new delta variant wave is sweeping through the globe. While previous reports consistently have demonstrated worse prognoses for patients with existing cardiovascular disease than for those without, new studies are showing a possible link between SARS-CoV-2 infection and an increased incidence of new-onset heart disease and diabetes, regardless of disease severity. If this trend is true, with hundreds of millions infected, the disease burden could portend a potentially troubling increase in heart disease and diabetes in the future. Focusing on heart failure in this review, we discuss the current data at the intersection of COVID, heart failure, and diabetes, from clinical findings to potential mechanisms of how SARS-CoV-2 infection could increase the incidence of those pathologies. Additionally, we posit questions for future research areas regarding the significance for patient care.

Download Full-text

Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease—a nationwide study

European Heart Journal ◽

10.1093/eurheartj/ehaa874 ◽

2020 ◽

Cited By ~ 1

Author(s):

Maria Fedchenko ◽

Zacharias Mandalenakis ◽

Kok Wai Giang ◽

Annika Rosengren ◽

Peter Eriksson ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Congenital Heart Disease ◽

Heart Disease ◽

Older Patients ◽

Congenital Heart ◽

Long Term Outcomes ◽

Increased Risk ◽

New Onset

Abstract Aims We aimed to describe the risk of myocardial infarction (MI) in middle-aged and older patients with congenital heart disease (ACHD) and to evaluate the long-term outcomes after index MI in patients with ACHD compared with controls. Methods and results A search of the Swedish National Patient Register identified 17 189 patients with ACHD (52.2% male) and 180 131 age- and sex-matched controls randomly selected from the general population who were born from 1930 to 1970 and were alive at 40 years of age; all followed up until December 2017 (mean follow-up 23.2 ± 11.0 years). Patients with ACHD had a 1.6-fold higher risk of MI compared with controls [hazard ratio (HR) 1.6, 95% confidence interval (CI) 1.5–1.7, P < 0.001] and the cumulative incidence of MI by 65 years of age was 7.4% in patients with ACHD vs. 4.4% in controls. Patients with ACHD had a 1.4-fold increased risk of experiencing a composite event after the index MI compared with controls (HR 1.4, 95% CI 1.3–1.6, P < 0.001), driven largely by the occurrence of new-onset heart failure in 42.2% (n = 537) of patients with ACHD vs. 29.5% (n = 2526) of controls. Conclusion Patients with ACHD had an increased risk of developing MI and of recurrent MI, new-onset heart failure, or death after the index MI, compared with controls, mainly because of a higher incidence of newly diagnosed heart failure in patients with ACHD. Recognizing and managing the modifiable cardiovascular risk factors should be of importance to reduce morbidity and mortality in patients with ACHD.

Download Full-text

Electrocardiographic Predictors of New-Onset Heart Failure in Men and in Women Free of Coronary Heart Disease (from the Atherosclerosis in Communities [ARIC] Study)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2007.06.036 ◽

2007 ◽

Vol 100 (9) ◽

pp. 1437-1441 ◽

Cited By ~ 48

Author(s):

Pentti M. Rautaharju ◽

Ron J. Prineas ◽

Joy Wood ◽

Zhu-Ming Zhang ◽

Richard Crow ◽

...

Keyword(s):

Heart Failure ◽

Coronary Heart Disease ◽

Heart Disease ◽

Aric Study ◽

New Onset

Download Full-text

Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic Heart Disease Patients With Heart Failure: A Retrospective Study

Frontiers in Cardiovascular Medicine ◽

10.3389/fcvm.2021.711203 ◽

2021 ◽

Vol 8 ◽

Author(s):

Cheng Liu ◽

Yanxian Lai ◽

Tianwang Guan ◽

Qingchun Zeng ◽

Jingxian Pei ◽

...

Keyword(s):

Heart Failure ◽

Heart Disease ◽

Rheumatic Heart Disease ◽

Cox Proportional Hazards ◽

Retrospective Case ◽

Patients With Heart Failure ◽

All Cause Mortality ◽

Rheumatic Heart ◽

New Onset

Objective: This retrospective, case–control study was executed to assess the effects of digoxin (DGX) use approaches [continuous use of DGX (cDGX) vs. intermittent use of DGX (iDGX)] on the long-term prognosis in rheumatic heart disease (RHD) patients with heart failure (HF).Methods: A total of 642 RHD patients were enrolled to this study after propensity matching. The associations of DGX application approaches with the risks of all-cause mortality, cardiovascular death (CVD), HF re-hospitalization (1-, 3-, and 5-year), and new-onset atrial fibrillation (AF) were analyzed by multivariate Cox proportional hazards or binary logistic regression models, respectively.Results: cDGX was associated with increased risks of all-cause mortality (adjusted HR = 1.84, 95% CI: 1.27–2.65, P = 0.001) and CVD (adjusted HR = 2.23, 95% CI: 1.29–3.83, P = 0.004) in RHD patients with HF compared to iDGX. With exception of 1-year HF re-hospitalization risk, cDGX was associated with increased HF re-hospitalization risk of 3-year (adjusted OR = 1.53, 95% CI: 1.03–2.29, P = 0.037) and 5-year (adjusted OR = 1.61, 95% CI: 1.05–2.50, P = 0.031) as well as new-onset AF (adjusted OR = 2.06, 95% CI: 1.09–3.90, P = 0.027).Conclusion: cDGX was significantly associated with increased risks of all-cause mortality, CVD, medium-/long-term HF re-hospitalization, and new-onset AF in RHD patients with HF.

Download Full-text